BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
BioCentury | Jul 10, 2020

With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund

Newly launched Eir Ventures believes the Nordic countries offer an investment opportunity rich in science that has been underserved by VCs. To help fill the gap, the firm has raised the first €76 million ($85.5...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Incoming CEO David Loew will arrive as Ipsen tries to recover from setbacks that have hobbled development of palovarotene, one of its two candidates to treat rare disease FOP and the key to its billion-dollar...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to treat...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

Reports that the novel coronavirus lingers in the stools of COVID-19 patients has put a spotlight on the safety risks of gut microbiome therapies. As researchers sort out whether the virus is capable of fecal...
BioCentury | Apr 14, 2020

Blackstone makes largest-ever life sciences investment in Alnylam

Blackstone’s $2 billion investment in Alnylam is a departure from its other life sciences investments in size and scope, but the deal still fits the investor’s core model of focusing on products rather than companies....
BioCentury | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14. Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched...
Items per page:
1 - 10 of 213